Cell-culture telomere findings do not close the chain from a defined synthetic Epitalon exposure to human healthspan. Product identity, alternative telomere-lengthening pathways, durability and cancer-related consequences require separate tests.
This dated addendum adds selected evidence and tests that could resolve the remaining questions. It does not regrade the archived review.
Each question identifies a limit in the checked evidence. A missing search result alone does not establish a gap in the entire field.
Competing explanation: Human reports may concern different peptide preparations; culture responses may not occur at attainable exposure.
Discriminating test: Characterized product and human PK/PD study with validated telomerase assays, placebo, tissue/cell-composition controls and prespecified assay timing.
Competing explanation: ALT, clonal selection or changing cell composition may mimic elongation.
Discriminating test: Orthogonal telomere assays, single-cell/lineage assessment, washout follow-up and telomerase blockade/rescue in appropriate models.
Competing explanation: Antioxidant, circadian or transcriptional effects may act independently of telomere maintenance.
Discriminating test: Factorial pathway perturbation in models and prespecified human mediator measurements; require functional endpoints beyond a telomere surrogate.
Competing explanation: Preserving replication could improve selected tissues while facilitating malignant or premalignant clones.
Discriminating test: Long-duration independent safety and functional-outcome studies with tissue-relevant surveillance; distinguish surrogate change from clinical benefit.
Electronic publication dates are used where recorded, with issue years shown separately. This is a selected chronology, not a claim of scientific priority or independent replication for every entry.
Lifespan changes were reported after peptide exposure during development.
What it cannot establish: Nonhuman developmental exposure does not test adult human somatic telomerase mediation.
Peptide treatment induced telomerase-related activity and telomere elongation.
What it cannot establish: Culture evidence does not establish organismal delivery or clinical benefit.
Mean lifespan was unchanged while late-survivor and maximum lifespan measures increased.
What it cannot establish: Selected survival-tail outcomes are not interchangeable with mean lifespan or human healthspan.
Mortality comparisons concerned Thymalin and Epithalamin regimens.
What it cannot establish: These products are not the synthetic Epitalon tetrapeptide; do not transfer their efficacy claims.
Treated cells showed longer telomeres and continued dividing beyond the control passage limit.
What it cannot establish: Culture passage extension is not organismal aging reversal; pathway necessity was not established.
Longer genetically predicted telomeres were linked to higher risk of several cancers and lower risk of some other diseases.
What it cannot establish: Lifelong genetic effects are not a direct estimate of peptide-treatment safety.
Peptide exposure improved wound-healing-related cellular findings under high glucose.
What it cannot establish: An antioxidant/EMT effect does not demonstrate telomere-mediated human healthspan extension.
Telomere responses involved telomerase-related changes in normal cells and ALT-associated findings in cancer cells.
What it cannot establish: Cell models do not establish durable in vivo human mediation; corrected figures must be used.
Case-specific Consensus records assisted gap discovery, chronology and targeted paper questions. Shared template wording about an amyloid-specific Deep follow-up is not evidence of a Deep run for this topic; the dated source records establish the actual use and access limits. Primary identifiers, selected abstract passages, correction notices and available primary-body passages were cross-checked. Generated absence cells, duplicate milestones and unsupported access claims were rejected.
Materials/Methods Par7 and Results: named normal/cancer lines and unequal telomerase response. Correction PMID 41240216 replaces Figures 1–3; this update does not re-quantify images.
This focused addendum does not establish 50–70 complete primary Methods/Results examinations per review. Baseline reading receipts and scores retain their original scope.
Selected full-text checks: 1; abstract checks: 7; metadata-only anchors: 0. Complete-paper examinations credited in this update: 0.
New enrichment: HSEF v5.3 causal distinctions. Archived scorecard schema: 5.4; retained as recorded.
The 2025 correction states that incorrect versions of Figures 1–3 appeared and supplies replacements. It does not itself establish image duplication or fraud. Quantitative figure-based claims need appraisal against the corrected figures.
PMID 11087911 · DOI 10.1016/s0047-6374(00)00217-7
Selected abstract passages checked. Primary record and selected abstract passages checked; no complete-paper appraisal credited.
PMID 12937682 · DOI 10.1023/a:1025493705728
Selected abstract passages checked. Primary record and selected abstract passages checked; no complete-paper appraisal credited.
PMID 14501183 · DOI 10.1023/a:1025114230714
Selected abstract passages checked. Primary record and selected abstract passages checked; no complete-paper appraisal credited.
Selected abstract passages checked. Primary record and selected abstract passages checked; no complete-paper appraisal credited.
PMID 15455129 · DOI 10.1023/b:bebm.0000038164.49947.8c
Selected abstract passages checked. Primary record and selected abstract passages checked; no complete-paper appraisal credited.
PMID 28241208 · DOI 10.1001/jamaoncol.2016.5945
Selected abstract passages checked. Primary record and selected abstract passages checked; no complete-paper appraisal credited.
PMID 40908429 · DOI 10.1007/s10522-025-10315-x
Selected full-text passages checked. Materials/Methods Par7 and Results: named normal/cancer lines and unequal telomerase response. Correction PMID 41240216 replaces Figures 1–3; this update does not re-quantify images.
Linked notices: Correction 41240216
Correction 41240216 was read: it supplies replacement versions of Figures 1–3. Figure images were not independently reanalysed in this update.
PMID 40493162 · DOI 10.1007/s12015-025-10911-x
Selected abstract passages checked. Primary record and selected abstract passages checked; no complete-paper appraisal credited.
Read the dated addendum · Video script and storyboard insert · References (RIS) · References (BibTeX)